from furniture as the core business decreased 7.59 from the previous year. That caused from the management policy of some distribution channels in domestic to enhance the efficiency of expenses. Such
1.27 N/A 0.58% 0.00% Distribution costs (41.75 ) (24.14 ) (17.61 ) 72.95% (19.11%) (13.74%) Administrative expenses (95.74 ) (94.34 ) (1.40 ) 1.48% (43.82%) (53.71%) Other Expenses Impairment loss of
-27.5% -24.5% 2,120.4 1,782.4 -15.9% Other income 31.8 15.9 22.9 -28.1% +44.1% 51.7 38.7 -25.1% Selling and distribution expenses 587.2 536.7 463.7 -21.0% -13.6% 1,175.1 1,000.4 -14.9% Administrative
) % Revenue from sales and service 1,788.5 2,025.3 1,187.1 (236.8) (11.7) 601.4 50.7 Cost of sales and service 1,499.5 1,686.8 998.7 (187.3) (11.1) 500.8 50.1 Selling and distribution expenses 73.7 78.7 52.0
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
0.00 12.21 N/A 6.95% 0.00% Revenues from reduction of defaulted interest under the Court’s order 16.66 0.00 16.66 N/A 9.48% 0.00% Distribution costs (24.14 ) (26.13 ) (1.99 ) 7.62% (13.74%) (8.83
) % Revenue from sales and service 1,788.5 2,025.3 1,187.1 (236.8) (11.7) 601.4 50.7 Cost of sales and service 1,499.5 1,686.8 998.7 (187.3) (11.1) 500.8 50.1 Selling and distribution expenses 73.7 78.7 52.0
trustee, under Clause 20; (13) the trust’s disclosure of information, under Clause 21; (14) the distribution to the unit holders, under Clause 22; (15) the proposal for resolution and the general meeting of
. Increasing household debts and loan rejection rate of financial institutions are the major obstacles. In the past, the strategy of the Company emphasizes the development of large-scale projects focusing mainly
earnings are supported by the Feedstock and PET segments led by the ongoing stra- tegic acquisitions and improving margins respectively. Our HVA strategy continues to deliver enhancement to our earnings in